MX2020010421A - Combinaciones de composición de vacunas inductoras de células t y usos de las mismas. - Google Patents
Combinaciones de composición de vacunas inductoras de células t y usos de las mismas.Info
- Publication number
- MX2020010421A MX2020010421A MX2020010421A MX2020010421A MX2020010421A MX 2020010421 A MX2020010421 A MX 2020010421A MX 2020010421 A MX2020010421 A MX 2020010421A MX 2020010421 A MX2020010421 A MX 2020010421A MX 2020010421 A MX2020010421 A MX 2020010421A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- antigen
- immunogen
- vaccine composition
- fluorocarbon
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 230000002163 immunogen Effects 0.000 abstract 3
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En el presente documento se proporcionan combinaciones de vacunas y métodos para potenciar una respuesta inducida por células T específicas de antígeno en un sujeto que lo necesite. Los métodos combinan la vacunación sistémica con una primera composición que contiene un vector viral no replicante que codifica un antígeno o inmunógeno que contiene uno o más epítopos de células T CD8+; y/o una segunda composición con micelas que contienen péptidos unidos a fluorocarbono, en la que cada péptido unido al fluorocarburo tiene: i) de 15 a 75 residuos de aminoácidos de longitud; ii) del antígeno o inmunógeno de la primera composición; y iii) contiene uno o más de los epítopos de células T CD8+ de la primera composición del antígeno o inmunógeno para inducir células T CD8+ específicas de antígeno; y opcionalmente una tercera composición que comprende una composición inmunomoduladora.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652478P | 2018-04-04 | 2018-04-04 | |
| US201862652484P | 2018-04-04 | 2018-04-04 | |
| PCT/US2019/025902 WO2019195626A1 (en) | 2018-04-04 | 2019-04-04 | T-cell inducing vaccine composition combinations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010421A true MX2020010421A (es) | 2021-01-15 |
Family
ID=68101347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010421A MX2020010421A (es) | 2018-04-04 | 2019-04-04 | Combinaciones de composición de vacunas inductoras de células t y usos de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210236623A1 (es) |
| EP (1) | EP3773710A4 (es) |
| JP (1) | JP2021520414A (es) |
| KR (1) | KR20210005046A (es) |
| CN (1) | CN112638410A (es) |
| AU (1) | AU2019249232A1 (es) |
| BR (1) | BR112020020323A2 (es) |
| CA (1) | CA3096056A1 (es) |
| IL (1) | IL277719A (es) |
| MX (1) | MX2020010421A (es) |
| WO (1) | WO2019195626A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| WO2016101031A1 (en) | 2014-12-23 | 2016-06-30 | Davoodi Pty Ltd | Delivery apparatus, system and associated methods |
| JP2022526632A (ja) * | 2019-04-06 | 2022-05-25 | アルティミューン インコーポレーティッド | 広範囲及び持続性のインフルエンザワクチン |
| CN111041003A (zh) * | 2019-12-20 | 2020-04-21 | 畜科生物工程有限公司 | 一种重组鸭瘟病毒及其构建方法和应用 |
| US11957542B2 (en) * | 2020-04-30 | 2024-04-16 | Automed Patent Holdco, Llc | Sensing complete injection for animal injection device |
| WO2022015662A1 (en) * | 2020-07-12 | 2022-01-20 | Altimmune, Inc | Coronavirus immunogenic t cell epitope compositions and uses thereof |
| CN111979211B (zh) * | 2020-07-29 | 2021-11-30 | 扬州大学 | 一种能诱导抗鸡cGAS蛋白抗体的多肽及其应用 |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| CN114028552A (zh) * | 2021-10-27 | 2022-02-11 | 保定诺未科技有限公司 | 一种单核细胞负载lmp1蛋白的疫苗组合物及其制备方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2360254A1 (en) * | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| GB0716992D0 (en) * | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| WO2008099284A2 (en) * | 2007-01-12 | 2008-08-21 | The University Of Western Ontario | Hiv combination vaccine and prime boost method |
| CA2733203A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mtor inhibitors to enhance t cell immune responses |
| US8613936B2 (en) * | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
| WO2012083297A2 (en) * | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| CA2974237C (en) * | 2015-01-09 | 2021-07-20 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2019
- 2019-04-04 EP EP19780597.1A patent/EP3773710A4/en not_active Withdrawn
- 2019-04-04 MX MX2020010421A patent/MX2020010421A/es unknown
- 2019-04-04 US US17/044,952 patent/US20210236623A1/en not_active Abandoned
- 2019-04-04 JP JP2021503712A patent/JP2021520414A/ja active Pending
- 2019-04-04 CA CA3096056A patent/CA3096056A1/en active Pending
- 2019-04-04 AU AU2019249232A patent/AU2019249232A1/en not_active Abandoned
- 2019-04-04 WO PCT/US2019/025902 patent/WO2019195626A1/en unknown
- 2019-04-04 KR KR1020207031886A patent/KR20210005046A/ko unknown
- 2019-04-04 CN CN201980038045.9A patent/CN112638410A/zh active Pending
- 2019-04-04 BR BR112020020323-8A patent/BR112020020323A2/pt not_active Application Discontinuation
-
2020
- 2020-10-01 IL IL277719A patent/IL277719A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3096056A1 (en) | 2019-10-10 |
| AU2019249232A1 (en) | 2020-10-22 |
| WO2019195626A1 (en) | 2019-10-10 |
| BR112020020323A2 (pt) | 2021-01-05 |
| KR20210005046A (ko) | 2021-01-13 |
| JP2021520414A (ja) | 2021-08-19 |
| IL277719A (en) | 2020-11-30 |
| US20210236623A1 (en) | 2021-08-05 |
| EP3773710A1 (en) | 2021-02-17 |
| CN112638410A (zh) | 2021-04-09 |
| EP3773710A4 (en) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010421A (es) | Combinaciones de composición de vacunas inductoras de células t y usos de las mismas. | |
| EA201791806A1 (ru) | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов | |
| Lu | Heterologous prime–boost vaccination | |
| HRP20211566T1 (hr) | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe | |
| RU2015122368A (ru) | Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| EA200901060A1 (ru) | Новый способ и композиции | |
| JP2018504419A5 (es) | ||
| RU2008135433A (ru) | Гибриды рекомбинантных антител-белков стресса | |
| WO2014106123A8 (en) | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof | |
| IL273193B2 (en) | A method for safe induction of immunity against rsv | |
| TW200637910A (en) | Recombinant BCG strains with enhanced ability to escape the endosome | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
| MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| DK0880360T3 (da) | Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop | |
| WO2018055535A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| EA200701440A1 (ru) | Композиции для иммунизации против микобактерий | |
| MX2022014943A (es) | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. | |
| WO2022036142A3 (en) | Ras neoantigens and uses thereof | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| Faludi et al. | Recombinant Mycobacterium smegmatis vaccine candidates | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| EA202092200A1 (ru) | Индуцирующие т-клетки комбинации композиций вакцин и их применение |